There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Akebia Therapeutics Inc. (AKBA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0001, or -0.01%, to $1.0299. The Akebia Therapeutics Inc. has recorded 11,490 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.03 and fluctuated between $1.0600 as its day high and $0.9801 as its day low. The current market capitalization of Akebia Therapeutics Inc. is $163.38M. A total of 1.51 million shares were traded on the day, compared to an average of 1.83M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, AKBA has seen 0 BUY and 19 SELL insider trades, representing the acquisition of 0 and the disposition of 217,124 shares. Over the last 12 months, there were 12 BUYs and 21 SELLs from insiders. Insiders purchased 1,317,725 shares during that period but sold 222,838.
In the most recent transaction, Butler John P. sold 91,868 shares of AKBA for 0.88 per share on Mar 01. After the transaction, the CEO and President now owns 1,568,872 company shares. In a previous transaction on Mar 01, Dahan Michel sold 20,412 shares at 0.88 per share. AKBA shares that SVP, Chief Operating Officer owns now total 269,515.
Among the insiders who sold shares, Burke Steven Keith disposed of 14,123 shares on Mar 01 at a per-share price of $0.88. This resulted in the SVP, Chief Medical Officer holding 594,054 shares of AKBA after the transaction. In another insider transaction, Hadas Nicole R. sold 13,034 shares at $0.88 per share on Mar 01. Company shares held by the SVP, Chief Legal Officer now total 287,530.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for AKBA in the last 3 months, the mean price target is $2.00 with high estimates of $2.00 and low estimates of $2.00. In terms of 52-week highs and lows, AKBA has a high of $1.20 and a low of $0.24.
As of this writing, AKBA has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.11 per share and a lower estimate of -$0.11. The company reported an EPS of -$0.04 in the last quarter, which was 78.90% higher than expectations of -$0.19.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. AKBA’s latest balance sheet shows that the firm has $149.80M in Cash & Short Term Investments as of fiscal 2021. There were $136.05M in debt and $256.49M in liabilities at the time. Its Book Value Per Share was $0.05, while its Total Shareholder’s Equity was $76.46M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKBA is Buy with a score of 3.00.